tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RGNX Stock Latest News

REGENXBIO Faces Federal Securities Lawsuit Over Allegedly Concealed Gene Therapy Safety Risks
Class ActionREGENXBIO Faces Federal Securities Lawsuit Over Allegedly Concealed Gene Therapy Safety Risks
7d ago
RGNX
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
PremiumThe Fly
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
8d ago
RGNX
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
PremiumThe Fly
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
10d ago
RGNX
Controversial Prasad leaving FDA, NYT reports
PremiumThe Fly
Controversial Prasad leaving FDA, NYT reports
10d ago
AZN
BMY
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
PremiumCompany Announcements
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
12d ago
RGNX
Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026
PremiumMarket NewsBuy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026
12d ago
MGX
HELP
RegenXBio Earnings Call Balances Gene Therapy Risks
Premium
Company Announcements
RegenXBio Earnings Call Balances Gene Therapy Risks
13d ago
RGNX
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
Premium
The Fly
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
13d ago
RGNX
RegenXBio: Undervalued Multi‑Program Gene Therapy Story With Key RGX‑202 and RGX‑314 Catalysts Supporting a Buy Rating
PremiumRatings
RegenXBio: Undervalued Multi‑Program Gene Therapy Story With Key RGX‑202 and RGX‑314 Catalysts Supporting a Buy Rating
13d ago
RGNX
Regenxbio price target lowered to $42 from $45 at Stifel
PremiumThe Fly
Regenxbio price target lowered to $42 from $45 at Stifel
13d ago
RGNX
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
PremiumThe Fly
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
14d ago
RGNX
FDA review process for accelerated approval narrows, less predictable, WSJ says
PremiumThe Fly
FDA review process for accelerated approval narrows, less predictable, WSJ says
16d ago
CAPR
IRON
RGNX Earnings this Week: How Will it Perform?
PremiumPre-EarningsRGNX Earnings this Week: How Will it Perform?
16d ago
RGNX
LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM
Premium
Class Action
LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM
16d ago
RGNX
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock
Premium
Class Action
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock
16d ago
RGNX
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know
PremiumCompany Announcements
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know
20d ago
RGNX
Stifel says uniQure ‘understandably’ under pressure on Makary comments
PremiumThe Fly
Stifel says uniQure ‘understandably’ under pressure on Makary comments
21d ago
QURE
RGNX
Why Is UniQure Stock Down 30% Today?
PremiumMarket News
Why Is UniQure Stock Down 30% Today?
21d ago
QURE
RGNX
Leerink says FDA remarks likely targeted Regenxbio, not uniQure’s program
PremiumThe Fly
Leerink says FDA remarks likely targeted Regenxbio, not uniQure’s program
21d ago
QURE
RGNX
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
PremiumMarket NewsIs the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
22d ago
XBI
ERAS
Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says
Premium
The Fly
Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says
27d ago
RGNX
SRPT
Regenxbio price target lowered to $32 from $34 at H.C. Wainwright
Premium
The Fly
Regenxbio price target lowered to $32 from $34 at H.C. Wainwright
1M ago
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >